<DOC>
	<DOC>NCT00609622</DOC>
	<brief_summary>This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated before.</brief_summary>
	<brief_title>Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study was terminated on April 26, 2010 due to lack of efficacy, as determined during the interim analysis of data in April 2010, showing that the study did not meet its primary endpoint to demonstrate a statistically significant improvement in PFS. The decision to terminate the trial was not based on any safety concerns.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adenocarcinoma of the colon or rectum with locally advanced or metastatic disease Evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Eastern Cooperative Oncology Group (ECOG) 0 or 1 Previous treatment with Sutent, Avastin, or any other systemic therapy for locally advanced or metastatic colorectal cancer Less than 6 months since completion of adjuvant chemotherapy to documentation of recurrent disease History of cardiac disease Brain mets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>metastatic colorectal cancer sunitinib (Sutent) bevacizumab (Avastin) randomized study</keyword>
</DOC>